Vanessa King

Vanessa King is a Non-Executive Board Member at AZAFAROS B.V., bringing over 20 years of experience in the biotechnology industry.12 Here are some key details about her background and expertise:

Professional Experience

Biotechnology Leadership:: Vanessa King has held CEO positions at innovative biotechnology companies and served as an Entrepreneur in Residence at leading life science venture capital funds.1

Notable Roles::

• CEO of Cadent Therapeutics, where she led its transformation into a precision medicine neuroscience company with a clinical pipeline1
• Vice President of Business Development at deCODE Genetics, contributing to its acquisition by Amgen in 2012 for $415 million1
• Executive Chairman of Tiaki Therapeutics1
• Entrepreneur in Residence at Atlas Venture1
• Senior business development and operating positions at Amgen and Novartis1

Education

Vanessa King holds a PhD in Molecular Genetics from the University of Cambridge.13

Current Position

As a Non-Executive Board Member at AZAFAROS B.V., Vanessa King brings her extensive experience to help guide the company's strategic direction. AZAFAROS is a biotech company focused on developing treatments for rare genetic metabolic disorders, including lysosomal storage diseases and orphan diseases of the central nervous system.2

Expertise

Vanessa King's background demonstrates her expertise in:

• Biotechnology leadership
• Business development
• Precision medicine
• Neuroscience
• Strategic advisory

Her diverse experience in both executive roles and as a board member positions her well to contribute to AZAFAROS B.V.'s growth and development in the field of rare metabolic disorders.